Quince Therapeutics Rebrands as IRulya Therapeutics with New Leadership and $116M Cash Runway Through 2028
QNCX sits 94% above its 52-week low of $15.1.
Summary
Quince Therapeutics rebranded as IRulya Therapeutics with a new CEO, CFO, COO, and four new directors, while disclosing a $116M cash runway through 2028 and completing its Series C preferred stock conversion.
Key Events · Executive and Board Changes · QNCX
-
Corporate Rebranding to IRulya Therapeutics
Company name changed to IRulya Therapeutics Inc. effective October 9, 2026, with common stock moving to Nasdaq Capital Market under ticker IRLA on October 12, 2026.
-
Complete Leadership Overhaul
Brigette Roberts, M.D. appointed CEO, John Militello, CPA appointed CFO, and Keith Fandrick, Ph.D. appointed COO, effective October 8, 2026. Four directors resigned and four new directors were appointed.
-
Cash Runway Extended Through 2028
Cash balance of $116 million as of June 30, 2026 expected to fund operations through end of 2028, supporting Phase 2 data readouts for LAM-001 in BOS (Q1 2027), PH-ILD (Q1 2028), and SAPH (Q4 2028).
-
Series C Preferred Stock Conversion Completed
Stockholders approved conversion on October 6, 2026; Series C preferred stock automatically converts to common stock effective October 9, 2026, resulting in approximately 10,841,470 outstanding common shares.
Analysis · QNCX · Life Sciences
Quince Therapeutics completed its transformation into IRulya Therapeutics, installing an entirely new C-suite and board while rebranding to reflect its focus on LAM-001 for pulmonary diseases. The company disclosed a $116 million cash balance expected to fund operations through 2028, addressing the going-concern doubts raised in its August 10-Q. The Series C preferred stock conversion will result in approximately 10.84 million outstanding common shares, and the stock moves to Nasdaq Capital Market under ticker IRLA on October 12. This is a pivotal corporate reset following months of distress signals including a delisting notice and executive departures.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1061 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $29.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.9M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.